Problems › Should We Enter a New Market? › Healthcare Providers
Market attractiveness is the easy half. Right to win is the half that decides the outcome. This page works through it for healthcare providers specifically — including an unedited excerpt from a real analysis of a healthcare provider.
Market attractiveness is the easy half. Right to win is the half that decides the outcome. Healthcare providers carry a specific bind here — downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Until that is priced, cost per episode will keep moving for reasons nobody can attribute, and the debate about right to win will stay a matter of opinion.
New markets get evaluated on size and growth, both of which are knowable and neither of which predicts success. The predictive question is what you already have that transfers — a customer relationship, a distribution route, a cost position, a body of data — and what has to be built from nothing.
A market can be highly attractive and a bad idea for you specifically. The reverse is also true: a dull market where you have a structural advantage will usually outperform an exciting one where you start level with everyone.
The other discipline is a stated kill criterion before entry, because market entries are unusually good at consuming budget quietly for years on the argument that they are nearly there.
These three together are the signature. One on its own usually points somewhere else.
✓ The case rests mainly on market size and growth rate
✓ Nobody has written down what would make you stop
✓ The existing business is flat and the new market is being asked to fix it
The move that usually makes it worse. Entering because the core business has stalled, which takes management attention away from the problem that actually needs it.
It is for you if you run or finance a healthcare provider and the case rests mainly on market size and growth rate. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Protect and grow the 34% operating-income ASC engine by replacing retiring surgeons and steering 212k attributed lives to the ASC within 24 months.
| Investment required | $3.0-4.0M total over 24 months ($1.8-2.2M surgeon succession + retention bonuses; $1.2-1.8M referral-optimization platform and analytics) |
| Expected return | Incremental $4.8-6.4M annual ASC contribution margin by Month 24; payback 14-18 months on $3.0-4.0M investment; lifts group operating margin from 4.2% to 5.8-6.4%. |
| Revenue, year 1 | $202-208M (ASC case volume +4-6%) |
| Revenue, year 2 | $212-220M (ASC case volume +6-8%; physician retention +2-3%) |
| Revenue, year 3 | $225-235M (ASC contribution ≥40% of operating income) |
| Exit criteria | Strategy abandoned if, by Month 12, fewer than two qualified orthopaedic surgeon candidates have signed LOIs OR if ASC case volume has not grown at least 2% YoY; in either case, board must decide within 30 days whether to pivot to hospital-system sale process at 8-10× EBITDA. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Market Entry & Expansion Strategy, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
List what you already own that the new market values, and what a credible incumbent there owns that you do not. If the second list is longer and includes anything structural — distribution, regulation, data depth — entry is a build, not an extension.
Set the number before you start, and treat exceeding it as the kill criterion rather than as a reason to invest more. Most failed entries were never killed, only slowly starved.
Whichever reuses more of what you already have. Geography usually reuses the product and rebuilds distribution; a new segment usually reuses distribution and rebuilds the product. Whichever rebuild is smaller is the safer bet.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.